Another crucial pathway in BC is the PI3K/Akt/mammalian target of rapamycin (mTOR) signaling, wherein activating PIK3CA mutations, occurring in about 40% of hormone receptor HR+/HER2− MBCs, are driver events for tumorigenesis and tumor progression [57]. This evidence concerns the gene MTOR and breast cancer.